FDA accepts Acadia Pharma application for expanded use of Nuplazid

The FDA has accepted for review ACADIA Pharmaceuticals’ (NASDAQ:ACAD) supplemental marketing application seeking approval of Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis.

A agency’s action date is April 3, 2021.

The FDA approved Nuplazid in April 2016 for Parkinson’s disease psychosis.

https://seekingalpha.com/news/3592821-fda-accepts-acadia-pharma-application-for-expanded-use-of-nuplazid